2026-06-01T02:31:39Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1324802026-02-18T01:02:06Zcom_20.500.14352_14col_20.500.14352_15

Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine Guemes-Villahoz Noemi Talavero González Paula Porras-Ángel Paloma Bella Gala, Rafael Ruiz Pomeda, Alicia Martín García, Beatriz Hernández García, Elena GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA Shah Rakhee García Feijoo, Julián Gómez De Liaño Sánchez, María Rosario 617.7-089.243 617.75-053.2 Myopia control Children DIMS lenses Atropine Óptica y optometría Óptica oftálmica Pediatría 2209.15 Optometría 3212 Salud Publica 3201.10 Pediatría 3311.09 Lentes Received November 22, 2024 ; Accepted April 23, 2025 ; First published May 9, 2025 ; Online issue publication: August 20, 2025 This study is a collaborative research project supported by HOYA Vision Care. This project has counted on the collaboration of the Clinical Trials Unit of Hospital Clinico San Carlos (IUCEC) and the Research Methodology Support Unit (UAMI) belonging to the Instituto de Investigación Sanitaria San Carlos (IdISSC). We thank Dr Irene Schiavetti from the University of Genoa, Italy (Department of Health Sciences) for her support in conducting the statistical analyses, Nano-vision for donating the frames, Dr Hetel Bhakta for assistance and Prof Hakan Kaymak for age-matched myopia control ( AMMC) support. This study was previously presented as an abstract at the ARVO 2024 annual meeting, 19th IMC 2024 conference and the 27th EVER congress. Aim: To evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia. Methods: Randomised controlled trial conducted on children aged 4-16 years with myopia between -1.00D and -6.00D and astigmatism ≤2.00D. Children were randomly allocated into two groups: 0.025% atropine and SV spectacle lenses treatment group (group A), and 0.025% atropine and DIMS spectacle lenses treatment group (group B). Cycloplegic spherical equivalent refraction (SER) and axial length were measured at baseline, 6 and 12 months. Results: 102 patients completed the 12-month follow-up: n=49 in group A, mean age 9.50±2.78 years and n=53 in group B, mean age 9.90±2.47 years. At 12 months, the mean AL±SD change was 0.18±0.16 mm in group A and 0.07±0.16 mm in group B (mean difference: 0.11, 95% CI: 0.05 to 0.17; p≤0.001). Mean SER±SD progression at 12 months was -0.19±0.42D and -0.09±0.35D in groups A and B, respectively (p=0.13). 39.6% of children in group B had no axial elongation over 12 months compared with 12.2% of the children in group A (p=0.002). Conclusions: Combination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses. Although not significant, SER differences between groups were lower in group B. These findings support a potential additive effect of the two treatments. Depto. de Optometría y Visión Depto. de Inmunología, Oftalmología y ORL Fac. de Óptica y Optometría Instituto de Investigaciones Oftalmológicas Ramón Castroviejo Fac. de Medicina TRUE pub 2026-02-17T11:37:22Z 2026-02-17T11:37:22Z 2025-08-20 journal article VoR https://hdl.handle.net/20.500.14352/132480 0007-1161 10.1136/bjo-2024-326852 1468-2079 eng Guemes-Villahoz N, Talavero González P, Porras-Ángel P, Bella-Gala R, Ruiz-Pomeda A, Martin-Garcia B, Hernandez-Garcia E, Gomez de Liaño N, Shah R, Garcia-Feijoo J, Gomez-de-Liaño R. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Br J Ophthalmol. 2025 Aug 20;109(9):1074-1080. doi: 10.1136/bjo-2024-326852. PMID: 40345841; PMCID: PMC12418587. Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ open access application/pdf BMJ Group